The impact of an oral glucose load on IFN-γ-release in persons infected with Mycobacterium tuberculosis

Hans Johan Niklas Lorentsson; Christina Reinholdt Clausen; Daniel Faurholt-Jepsen; Katrine Bagge Hansen; Christian Ritz; Sidse Graff Jensen; Erik Michael Rasmussen; Anja Jørgensen; Troels Lillebaek; Filip Knop; Pernille Ravn

doi:10.1186/s12879-024-09920-x

The impact of an oral glucose load on IFN-γ-release in persons infected with Mycobacterium tuberculosis

Hans Johan Niklas Lorentsson^*
, Christina Reinholdt Clausen
, Daniel Faurholt-Jepsen
, Katrine Bagge Hansen
, Christian Ritz
, Sidse Graff Jensen
, Erik Michael Rasmussen
, Anja Jørgensen
, Troels Lillebaek
, Filip Knop
, Pernille Ravn

^*Kontaktforfatter

Københavns Universitet
Statens Serum Institut
Steno Diabetes Center Copenhagen
Herlev og Gentofte Hospital

Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › peer review

39 Downloads (Pure)

Abstract

BACKGROUND AND OBJECTIVE: To diagnose tuberculosis infection (TBI), whole blood is incubated with M.tuberculosis (Mtb)-specific peptides and the release of interferon-γ (IFN-γ) is measured in IFN-γ-release assays (IGRAs). Hyperglycaemia and fluctuations in blood glucose may modulate IFN-γ-release. Here, we investigated if glucose intake affects IFN-γ-release or IGRA results in IGRAs taken during an oral glucose tolerance test (OGTT).

METHODS: Persons with TB disease (TB) or TBI underwent a standard 75-g OGTT at the start and end of treatment for TB or TBI. Blood for the IGRA QuantiFERON-TB Gold Plus (QFT) containing Mtb-specific tubes (TB1 and TB2), a non-specific mitogen tube (MIT) and an empty control tube (NIL) was drawn at sample-timepoints -15 (baseline), 60, 90, 120 and 240 min during the OGTT. Blood glucose was measured in parallel at all timepoints. IFN-γ-release (after subtraction of NIL) at each timepoint was compared with baseline using linear-mixed-model analysis.

RESULTS: Twenty-four OGTTs from 14 participants were included in the final analysis. Compared to baseline, IFN-γ-release was increased at sample-timepoint 240 min for TB1; geometric mean (95% confidence interval) 3.0 (1.5-6.2) vs 2.5 (1.4-4.4) IU/mL (p = 0.047), and MIT; 182.6 (103.3-322.9) vs 146.0 (84.0-254.1) IU/mL (p = 0.002). Plasma glucose levels were not associated with IFN-γ-release and the QFT test results were unaffected by the OGTT.

CONCLUSION: Ingestion of glucose after a 10-h fast was associated with increased IFN-γ-release after 240 min in the MIT tube. However, there was no association between plasma glucose levels at the QFT sampling timepoint and IFN-γ-release. Furthermore, the QFT test results were not affected by glucose intake. The overall effect of an OGTT and prevailing plasma glucose levels on IFN-γ-release in IGRAs seem limited.

TRIAL REGISTRATION: Trial registration ID: NCT04830462 ( https://clinicaltrials.gov/study/NCT04830462 ). Registration date: 05-Apr-2021.

Originalsprog	Engelsk
Artikelnummer	1079
Tidsskrift	BMC Infectious Diseases
Vol/bind	24
Udgave nummer	1
Antal sider	7
ISSN	1471-2334
DOI	https://doi.org/10.1186/s12879-024-09920-x
Status	Udgivet - 30. sep. 2024

Bibliografisk note

Dokumenter og links

10.1186/s12879-024-09920-xLicens: CC BY

Open Access VersionForlagets udgivne version, 975 KBLicens: CC BY

SDU link

Tjek adgangen til materialet i Syddansk Universitetsbiblioteks søgemaskine

Citationsformater

Lorentsson, H. J. N., Clausen, C. R., Faurholt-Jepsen, D., Hansen, K. B., Ritz, C., Jensen, S. G., Rasmussen, E. M., Jørgensen, A., Lillebaek, T., Knop, F., & Ravn, P. (2024). The impact of an oral glucose load on IFN-γ-release in persons infected with Mycobacterium tuberculosis. BMC Infectious Diseases, 24(1), Artikel 1079. https://doi.org/10.1186/s12879-024-09920-x

@article{0e324b70c15549d28eac2153bbd18509,

title = "The impact of an oral glucose load on IFN-γ-release in persons infected with Mycobacterium tuberculosis",

abstract = "BACKGROUND AND OBJECTIVE: To diagnose tuberculosis infection (TBI), whole blood is incubated with M.tuberculosis (Mtb)-specific peptides and the release of interferon-γ (IFN-γ) is measured in IFN-γ-release assays (IGRAs). Hyperglycaemia and fluctuations in blood glucose may modulate IFN-γ-release. Here, we investigated if glucose intake affects IFN-γ-release or IGRA results in IGRAs taken during an oral glucose tolerance test (OGTT).METHODS: Persons with TB disease (TB) or TBI underwent a standard 75-g OGTT at the start and end of treatment for TB or TBI. Blood for the IGRA QuantiFERON-TB Gold Plus (QFT) containing Mtb-specific tubes (TB1 and TB2), a non-specific mitogen tube (MIT) and an empty control tube (NIL) was drawn at sample-timepoints -15 (baseline), 60, 90, 120 and 240 min during the OGTT. Blood glucose was measured in parallel at all timepoints. IFN-γ-release (after subtraction of NIL) at each timepoint was compared with baseline using linear-mixed-model analysis.RESULTS: Twenty-four OGTTs from 14 participants were included in the final analysis. Compared to baseline, IFN-γ-release was increased at sample-timepoint 240 min for TB1; geometric mean (95\% confidence interval) 3.0 (1.5-6.2) vs 2.5 (1.4-4.4) IU/mL (p = 0.047), and MIT; 182.6 (103.3-322.9) vs 146.0 (84.0-254.1) IU/mL (p = 0.002). Plasma glucose levels were not associated with IFN-γ-release and the QFT test results were unaffected by the OGTT.CONCLUSION: Ingestion of glucose after a 10-h fast was associated with increased IFN-γ-release after 240 min in the MIT tube. However, there was no association between plasma glucose levels at the QFT sampling timepoint and IFN-γ-release. Furthermore, the QFT test results were not affected by glucose intake. The overall effect of an OGTT and prevailing plasma glucose levels on IFN-γ-release in IGRAs seem limited.TRIAL REGISTRATION: Trial registration ID: NCT04830462 ( https://clinicaltrials.gov/study/NCT04830462 ). Registration date: 05-Apr-2021.",

keywords = "Adult, Aged, Female, Humans, Male, Middle Aged, Blood Glucose/analysis, Glucose/administration \& dosage, Glucose Tolerance Test, Interferon-gamma/blood, Interferon-gamma Release Tests/methods, Mycobacterium tuberculosis/immunology, Tuberculosis/blood",

author = "Lorentsson, \{Hans Johan Niklas\} and Clausen, \{Christina Reinholdt\} and Daniel Faurholt-Jepsen and Hansen, \{Katrine Bagge\} and Christian Ritz and Jensen, \{Sidse Graff\} and Rasmussen, \{Erik Michael\} and Anja J{\o}rgensen and Troels Lillebaek and Filip Knop and Pernille Ravn",

note = "{\textcopyright} 2024. The Author(s).",

year = "2024",

month = sep,

day = "30",

doi = "10.1186/s12879-024-09920-x",

language = "English",

volume = "24",

journal = "BMC Infectious Diseases",

issn = "1471-2334",

publisher = "BioMed Central",

number = "1",

}

TY - JOUR

T1 - The impact of an oral glucose load on IFN-γ-release in persons infected with Mycobacterium tuberculosis

AU - Lorentsson, Hans Johan Niklas

AU - Clausen, Christina Reinholdt

AU - Faurholt-Jepsen, Daniel

AU - Hansen, Katrine Bagge

AU - Ritz, Christian

AU - Jensen, Sidse Graff

AU - Rasmussen, Erik Michael

AU - Jørgensen, Anja

AU - Lillebaek, Troels

AU - Knop, Filip

AU - Ravn, Pernille

PY - 2024/9/30

Y1 - 2024/9/30

N2 - BACKGROUND AND OBJECTIVE: To diagnose tuberculosis infection (TBI), whole blood is incubated with M.tuberculosis (Mtb)-specific peptides and the release of interferon-γ (IFN-γ) is measured in IFN-γ-release assays (IGRAs). Hyperglycaemia and fluctuations in blood glucose may modulate IFN-γ-release. Here, we investigated if glucose intake affects IFN-γ-release or IGRA results in IGRAs taken during an oral glucose tolerance test (OGTT).METHODS: Persons with TB disease (TB) or TBI underwent a standard 75-g OGTT at the start and end of treatment for TB or TBI. Blood for the IGRA QuantiFERON-TB Gold Plus (QFT) containing Mtb-specific tubes (TB1 and TB2), a non-specific mitogen tube (MIT) and an empty control tube (NIL) was drawn at sample-timepoints -15 (baseline), 60, 90, 120 and 240 min during the OGTT. Blood glucose was measured in parallel at all timepoints. IFN-γ-release (after subtraction of NIL) at each timepoint was compared with baseline using linear-mixed-model analysis.RESULTS: Twenty-four OGTTs from 14 participants were included in the final analysis. Compared to baseline, IFN-γ-release was increased at sample-timepoint 240 min for TB1; geometric mean (95% confidence interval) 3.0 (1.5-6.2) vs 2.5 (1.4-4.4) IU/mL (p = 0.047), and MIT; 182.6 (103.3-322.9) vs 146.0 (84.0-254.1) IU/mL (p = 0.002). Plasma glucose levels were not associated with IFN-γ-release and the QFT test results were unaffected by the OGTT.CONCLUSION: Ingestion of glucose after a 10-h fast was associated with increased IFN-γ-release after 240 min in the MIT tube. However, there was no association between plasma glucose levels at the QFT sampling timepoint and IFN-γ-release. Furthermore, the QFT test results were not affected by glucose intake. The overall effect of an OGTT and prevailing plasma glucose levels on IFN-γ-release in IGRAs seem limited.TRIAL REGISTRATION: Trial registration ID: NCT04830462 ( https://clinicaltrials.gov/study/NCT04830462 ). Registration date: 05-Apr-2021.

AB - BACKGROUND AND OBJECTIVE: To diagnose tuberculosis infection (TBI), whole blood is incubated with M.tuberculosis (Mtb)-specific peptides and the release of interferon-γ (IFN-γ) is measured in IFN-γ-release assays (IGRAs). Hyperglycaemia and fluctuations in blood glucose may modulate IFN-γ-release. Here, we investigated if glucose intake affects IFN-γ-release or IGRA results in IGRAs taken during an oral glucose tolerance test (OGTT).METHODS: Persons with TB disease (TB) or TBI underwent a standard 75-g OGTT at the start and end of treatment for TB or TBI. Blood for the IGRA QuantiFERON-TB Gold Plus (QFT) containing Mtb-specific tubes (TB1 and TB2), a non-specific mitogen tube (MIT) and an empty control tube (NIL) was drawn at sample-timepoints -15 (baseline), 60, 90, 120 and 240 min during the OGTT. Blood glucose was measured in parallel at all timepoints. IFN-γ-release (after subtraction of NIL) at each timepoint was compared with baseline using linear-mixed-model analysis.RESULTS: Twenty-four OGTTs from 14 participants were included in the final analysis. Compared to baseline, IFN-γ-release was increased at sample-timepoint 240 min for TB1; geometric mean (95% confidence interval) 3.0 (1.5-6.2) vs 2.5 (1.4-4.4) IU/mL (p = 0.047), and MIT; 182.6 (103.3-322.9) vs 146.0 (84.0-254.1) IU/mL (p = 0.002). Plasma glucose levels were not associated with IFN-γ-release and the QFT test results were unaffected by the OGTT.CONCLUSION: Ingestion of glucose after a 10-h fast was associated with increased IFN-γ-release after 240 min in the MIT tube. However, there was no association between plasma glucose levels at the QFT sampling timepoint and IFN-γ-release. Furthermore, the QFT test results were not affected by glucose intake. The overall effect of an OGTT and prevailing plasma glucose levels on IFN-γ-release in IGRAs seem limited.TRIAL REGISTRATION: Trial registration ID: NCT04830462 ( https://clinicaltrials.gov/study/NCT04830462 ). Registration date: 05-Apr-2021.

KW - Adult

KW - Aged

KW - Female

KW - Humans

KW - Male

KW - Middle Aged

KW - Blood Glucose/analysis

KW - Glucose/administration & dosage

KW - Glucose Tolerance Test

KW - Interferon-gamma/blood

KW - Interferon-gamma Release Tests/methods

KW - Mycobacterium tuberculosis/immunology

KW - Tuberculosis/blood

U2 - 10.1186/s12879-024-09920-x

DO - 10.1186/s12879-024-09920-x

M3 - Journal article

C2 - 39350021

SN - 1471-2334

VL - 24

JO - BMC Infectious Diseases

JF - BMC Infectious Diseases

IS - 1

M1 - 1079

ER -

The impact of an oral glucose load on IFN-γ-release in persons infected with Mycobacterium tuberculosis

Abstract

Bibliografisk note

Dokumenter og links

SDU link

Fingeraftryk

Citationsformater